Emylcamate
 | |
| Clinical data | |
|---|---|
| ATC code | N05BC03 (WHO) |
| Identifiers | |
| |
| CAS Number |
78-28-4  |
| PubChem (CID) | 6526 |
| ChemSpider |
6278 |
| UNII |
KCJ747D3R4 |
| KEGG |
D07317 |
| ChEMBL | CHEMBL2104208 |
| ECHA InfoCard | 100.001.002 |
| Chemical and physical data | |
| Formula | C7H15NO2 |
| Molar mass | 145.20 g·mol−1 |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.
A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared to meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:
| Meprobamate | Emylcamate | Effect |
|---|---|---|
| 175 | 123 | ED50 (mg/kg) |
| 600 | 550 | LD50 (mg/kg) |
| 3.4 | 4.4 | Therapeutic index |
Emylcamate also has a faster intra-parenteral onset then meprobabamate, 3 minutes compared to 35. [1]
References
- ↑ Melander, B. (1959). "Emylcamate, A Potent Tranquillizing Relaxant". Journal of Medicinal and Pharmaceutical Chemistry. 1 (5): 443–457. doi:10.1021/jm50006a003.
- Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia (Portuguese)
- The Comparative Toxicogenomics Database: Emylcamate.
- BIAM: Emylcamate (French).
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.